What do these results mean for individuals with mCSPC?

Patients with metastatic castration-sensitive prostate cancer (mCSPC) who have BRCA1/2 mutations often don't respond well to current treatment. These patients typically experience rapid disease progression and may require additional treatment sooner compared to those without *BRCA1/2* mutations. This underscores the urgent need for the development of more effective, targeted therapeutic strategies for this patient subgroup.

What was the purpose of this study?

- This study of patients with mCSPC treated with androgen receptor pathway inhibitors (ARPIs) aimed to assess:
 - Time to patients receiving next treatment
 - Time to development of castration resistant cancer
- Outcomes were compared between patients with and without DNA repair gene mutations

How was the study carried out?

- · The study was conducted by extracting data from a database of patients with mCSPC in the United States
- · Researchers focused on adult male patients who initiated treatment with ARPIs and screened for the presence of DNA mutations particularly in homologous recombination repair (HRR) genes
- · Patients were stratified into two cohorts: those with HRR gene mutations (HRR+) and those without (HRR-)
- Within the HRR+ group, further categorization was made based on the presence of *BRCA1/2* mutations
- The primary endpoints were time-to-next-treatment (TTNT), reflecting the duration until the initiation of subsequent therapy, and time-tocastration-resistance (TTCR), indicating the time until the development of castration resistance

What were the limitations of the study?

- The study had a limited number of patients (833 in total), which might affect the reliability of the results
- It focused only on patients from the US, so the findings might not \mathcal{O} apply to people in other countries

Real-world time-to-next-treatment and time-to-castration-resistance among patients with metastatic castration-sensitive prostate cancer using androgen-receptor pathway inhibitors with and without homologous recombination repair mutations

Daniel W. Lin¹, Sabree Burbage², Carmine Rossi³, Ibrahim Khilfeh², Lilian Diaz³, Yuxi Wang³, Dominic Pilon³, Gordon Brown⁴, Neal Shore⁵, Benjamin Lowentritt⁶, Heather H. Cheng¹, Mehmet A. Bilen⁷

¹Fred Hutch Cancer Center, Seattle, WA, USA; ²Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA; ³Analysis Group, Inc., Montréal, QC, Canada; ⁴New Jersey Urology, Sewell, NJ, USA; ⁵Atlantic Urology Clinics, Myrtle Beach, SC, USA; ⁶Chesapeake Urology, Baltimore, MD, USA; ⁷Emory University School of Medicine, Atlanta, GA, USA

What were the results?

Patients with BRCA1/2 gene changes had faster worsening of their condition and needed new treatments sooner than those with other gene mutations or no gene mutations




Who was in the study?

There were 833 patients with mCSPC who had started ARPI treatment and tested for a HRR before the cancer was deemed castration resistant

- A total of 125 patients were HRR+. of which 88 were BRCA+
- A total of 620 patients were HRR-
- The average age was 70 years for patients with HRR- and 71 years for patients with HRR+, and BRCA+ mutations
- Approximately two-thirds of patients were White
- Enzalutamide and abiraterone acetate were the most frequently used ARPIs
- Most patients were treated at communitybased oncology practices



Proportion of patients who received a next treatment by 24 months:



Median time-to-nexttreatment:

Proportion of patients who developed castration resistance by 24 months:



Median time-to-castrationresistance:

resistance compared to the other cohorts (HRR+ and HRR-)

Ś	Glossary of Terms					
	ARPI	Androgen receptor pathway inhibitors are drugs used to treat prostate cancer by inhibiting the androgen receptor pathway, a key driver of prostate cancer cell growth.	HRR	Homologous recombination repair is a process that uses an undamaged, homologous sequence as a template to repair DNA double-strand breaks, ensuring high-fidelity repair and genomic stability.	TTCR	Time-to-castration-resistance refers to the duration from the start of primary androgen deprivation therapy to the onset of castration-resistant prostate cancer.
	BRCA1/2	A tumor suppressor gene that is involved in preventing the uncontrolled growth of cells.	mCSPC	A type of prostate cancer that has spread to other parts of the body but is still responsive to treatments that lower testosterone.	TTNT	Time-to-next-treatment is a measure of the duration of time between the start of one treatment and the initiation of the next treatment line.





Scan the QR code for the full poster